Arcus Biosciences, Inc.
RCUS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -83.8% | 471.4% | 7.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 92.3% | 100% | 100% | 100% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -500% | 2.5% | -385.7% | -342.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -519.2% | -5% | -400% | -361.5% |
| EPS Diluted | -1.27 | 0.043 | -1.14 | -1.03 |
| % Growth | -3,026.3% | 103.8% | -10.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |